bioAffinity Technologies, Inc.
BIAF- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001712762
No open-market purchases or sales by bioAffinity Technologies, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $782.5K in total; no superinvestor holds it.
Other share classesBIAFW
Q1 2025 vs. Q4 2024
How the institutions holding bioAffinity Technologies, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 16 | 17 | +1 |
| Shares | 535.7K | 512.3K | −23.4K (−4.4%) |
| Value | $497.4K | $132.3K | −$365.1K (−73.4%) |
New holders (4)
Institutions that held bioAffinity Technologies, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Warberg Asset Management LLC | 22,500 | $5.87K | 0.00% |
| Van Hulzen Asset Management, LLC | 16,012 | $4.16K | 0.00% |
| HRT Financial LP | 18,841 | $4.00K | 0.00% |
| Barclays PLC | 3,181 | $827 | 0.00% |
Sold out (3)
Institutions that held bioAffinity Technologies, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Two Sigma Securities, LLC | 14,420 | $13.1K |
| Citadel Advisors LLC | 13,264 | $12.4K |
| Oarsman Capital, Inc. | 2,448 | $2.23K |